NCT06188702

Who might be able to join this trial:

• You are expected to live for at least 3 months or more.
• You are generally active and able to care for yourself, with little to no limitation in daily activities (confirm with trial site for exact fitness level required).
• You are able and willing to use a highly effective form of birth control if required.
• You have been diagnosed with an advanced or spreading solid tumor (most types accepted, with some exceptions) that can be measured on scans, and your cancer has gotten worse after at least one previous treatment, and no other standard treatments are available for you.
• Your tumor has been tested and confirmed to have a specific genetic change called a homozygous MTAP gene deletion, found through a specific type of genetic test.
• Your kidneys, liver, and other organs are working well enough to take part (confirm with trial site for exact requirements).
• If joining the early phase (Phase 1), you are willing to have a small sample of your tumor taken before and during treatment (with some exceptions for safety reasons).
• If joining the later phase (Phase 2), you may need to provide a fresh tumor sample or a recently stored tissue sample, depending on your cancer type and which part of the trial you are joining.
• If you are in China and being considered for certain parts of the trial, you may need an additional genetic test to confirm the MTAP deletion.
• Depending on which specific group (arm) of the trial you are joining, you may need to have one of the following cancer types that has spread or cannot be surgically removed, and has gotten worse after at least one standard treatment: lung cancer (non-small cell type), bile duct cancer, pancreatic cancer, stomach or oesophageal cancer, or another type of advanced solid tumour with the MTAP gene deletion.

Who may not be able to join:

• You are unable to swallow tablets or capsules, or have a medical condition or past surgery that could affect how your body absorbs the study drug.
• You have another active cancer (with some exceptions such as certain early-stage or non-spreading cancers — confirm with trial site).
• You have had a serious allergic reaction to any ingredient in the study drug in the past.
• You have had major surgery within 4 weeks before starting the trial, or have not fully recovered from surgery.
• You have a condition called Gilbert's syndrome (a liver condition affecting how the body processes bilirubin).
• You have a known serious heart or blood vessel condition.
• You have had a blood clot in a vein or in the lungs within 4 weeks before starting the trial.
• You currently have active cancer that has spread to the brain.
• You have received cancer treatment or radiotherapy less than 2 weeks before the start of the trial.
• You are pregnant or currently breastfeeding.
• You are a woman who could become pregnant and have a positive pregnancy test within 7 days before starting the trial.
• You have had a hole or abnormal connection in your digestive tract, or a specific type of fistula near the food pipe, within the last 6 months.
• You have a severe or uncontrolled active infection.
• You have previously been treated with a MAT2A or PRMT5 inhibitor (a specific type of cancer drug — confirm with trial site if unsure).
• You have a medical condition that makes your skin unusually sensitive to sunlight (such as lupus or solar urticaria).
• If you are being considered for a specific drug combination in this trial, you may not be eligible if you have certain eye conditions, including: a past history of drug-related damage to the retina or optic nerve, uncontrolled glaucoma, existing macular degeneration, ongoing moderate-to-severe retina or optic nerve problems, or any other known active retinal disease.

Important: Always verify eligibility with the trial site directly before applying.